Bayer sues COVID vaccine makers over mRNA technology

Reuters
01/07
UPDATE 1-Bayer sues COVID vaccine makers over mRNA technology

Adds links to lawsuits in paragraphs 2 and 3, Moderna response and requests for defendant comments in paragraph 4

By Blake Brittain

Jan 6 (Reuters) - Bayer's BAYGn.DE Monsanto sued COVID-19 vaccine makers Pfizer PFE.N, BioNTech 22UAy.DE and Moderna MRNA.O in Delaware federal court on Tuesday for allegedly misusing its messenger RNA technology in manufacturing their vaccines, a Bayer spokesperson confirmed.

The patent infringement lawsuits said the companies copied technology developed by Monsanto in the 1980s for strengthening mRNA in crops in order to stabilize the genetic material used in their vaccines.

Bayer separately filed a similar lawsuit against Johnson & Johnson JNJ.N in New Jersey federal court on Tuesday, arguing that a DNA-based process J&J used in manufacturing its shots infringed the patent.

A Moderna spokesperson said the company is aware of the lawsuit and will defend itself. Spokespeople for Pfizer, BioNTech and Johnson & Johnson did not immediately respond to requests for comment.

Bayer's complaints add to a web of patent lawsuits over the blockbuster COVID shots, which include an ongoing lawsuit filed by Moderna against Pfizer in 2022.

Bayer was not involved in developing COVID vaccines and does not make or sell any version of them. It asked the courts for an unspecified amount of monetary damages and said it was not seeking to block the companies from manufacturing their vaccines.

Pfizer and BioNTech earned more than $3.3 billion in revenue from global sales of their vaccine Comirnaty in 2024, while Moderna earned $3.2 billion from its Spikevax, according to company reports, a fraction of their sales at the height of the pandemic.

Johnson & Johnson stopped selling its COVID vaccine in the United States in 2023.

Bayer's lawsuits said Monsanto scientists pioneered technology in the 1980s for reducing mRNA instability to make more pest-resistant crops. Bayer alleged that Pfizer and Moderna utilized technology for improving the stability of mRNA that infringes one of its patents.

(Reporting by Blake Brittain in WashingtonEditing by Bill Berkrot)

((blake.brittain@tr.com; +1 (202) 938-5713))

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10